| Prediabetes: To treat or not to treat? | |
| | |
MedLine Citation:
|
PMID: 22020287 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The incidence of diabetes is continuously increasing worldwide. Pre-diabetes (defined as impaired glucose tolerance, impaired fasting glucose or both) represents an intermediate state, which often progresses to overt diabetes within a few years. In addition, pre-diabetes may be associated with increased risk of microvascular and macrovascular complications. Thus, reverting a pre-diabetic state as well as preventing the development of diabetes represents enormous challenge for the clinician. Lifestyle modification in pre-diabetic individuals was found particularly effective in the prevention of diabetes. However, compliance to lifestyle modification measures can be a crucial problem in the everyday clinical practice, especially in developing countries. During the last decade many studies support the use of anti-diabetic treatment schemes in pre-diabetic subjects to be advantageous. The American Diabetes Prevention Program (DPP) as well as other minor studies and meta-analyses has convincingly demonstrated the efficacy of metformin in this patient group. In addition, results of the 10year DPP follow up have recently been published, demonstrating the long term safety and sustainability of metformin treatment benefits in this population. In contrast to metformin, the evidence from the use of other anti-diabetic agents (thiazolidinediones, a-glucosidase inhibitors, incretin mimetics) in pre-diabetic individuals is rather inadequate and prospective data is further needed. Furthermore, large scale studies with hard clinical endpoints are needed to delineate the effect of pre-diabetes treatment on macro- and microvascular complications. In conclusion, several strategies of patient management, mainly lifestyle modification and pharmacological interventions can prevent diabetes development in subjects diagnosed with pre-diabetes or even revert pre-diabetic state. However, whether this biochemical improvement can be translated into actual clinical benefit remains to be established. |
| | |
Authors:
|
Elisavet Moutzouri; Vasilis Tsimihodimos; Evangelos Rizos; Moses Elisaf |
Related Documents
:
|
3555887 - Bisphosphorylated metabolites of glycerate, glucose, and fructose: functions, metabolis... 16496277 - Major influence of liver function itself but not of immunosuppression determines glucos... 15252027 - Effect of insulin on caveolin-enriched membrane domains in rat liver. 21616737 - A model of translational research for diabetes prevention in low and middle-income coun... 11559967 - Association of nephropathy and retinopathy, blood pressure, age in newly diagnosed type... 11456267 - Effects of heat exposure on adrenergic modulation of insulin and glucagon secretion in ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-10-12 |
Journal Detail:
|
Title: European journal of pharmacology Volume: - ISSN: 1879-0712 ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011. Published by Elsevier B.V. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dietary fatty acids linking postprandial metabolic response and chronic diseases.
Next Document: Drug discovery targeting human 5-HT(2C) receptors: Residues S3.36 and Y7.43 impact ligand-Binding po...